Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer : An Update
Guallar Garrido, Sandra (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Julián Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)

Data:	2020
Resum:	Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have been in shock during the last six years since manufacturing restrictions on the production of the first-option medicine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), have resulted in worldwide shortages. This shortage of BCG has led to a rethinking of the established treatment guidelines for the rationing of the administration of BCG. Some possible schedule modifications consist of a decrease in the length of maintenance treatment, a reduction in the dose of BCG in intravesical instillations or the use of different BCG substrains. All these strategies have been considered valuable in times of BCG shortage. In addition, the lack of availability of BCG has also led to the general recognition of the need to find new treatment options for these patients so that they are not dependent on a single treatment. Few alternatives are committed to definitively replacing BCG intravesical instillations, but several options are being evaluated to improve its efficacy or to combine it with other chemotherapeutic or immunotherapeutic options that can also improve its effect. In this article, we review the current state of the treatment with BCG in terms of all of the aforementioned aspects.
Ajuts:	Ministerio de Economía y Competitividad SAF2015-63867-R Agencia Estatal de Investigación RTI2018-098777-B-I00 Agència de Gestió d'Ajuts Universitaris i de Recerca 2017/SGR-229
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Mycobacteria ; Nonmuscle invasive ; Immunotherapy ; Alternative treatment
Publicat a:	ImmunoTargets and Therapy, Vol. 9 (February 2020) , p. 1-11, ISSN 2253-1556

DOI: 10.2147/ITT.S202006
PMID: 32104666

11 p, 459.6 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats